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Abstract 
AIM: To develop and validate a simple and sensitive method using liquid chromatography-mass 
spectrometry (LC-MS) for quantification of articaine, and its major metabolite articainic acid, in 
plasma of red deer (Cervus elaphus), and to investigate the pharmacokinetics of articaine 
hydrochloride and articainic acid in red deer following S/C administration of articaine 
hydrochloride as a complete ring block around the antler pedicle.  
METHODS: The LC-MS method was validated by determining linearity, sensitivity, recovery, 
carry-over and repeatability. Articaine hydrochloride (40 mg/mL) was administered S/C to six 
healthy male red deer, at a dose of 1 mL/cm of pedicle circumference, as a complete ring block 
around the base of each antler. Blood samples were collected at various times over the following 12 
hours. Concentrations in plasma of articaine and articainic acid were quantified using the validated 
LC-MS method. Pharmacokinetic parameters of articaine and articainic acid were estimated using 
non-compartmental analysis.  
RESULTS: Calibration curves were linear for both articaine and articainic acid. The limits of 
quantifications for articaine and articainic acid were 5 and 10 ng/mL, respectively. Extraction 
recoveries were >72% for articaine and >68% for articainic acid. After S/C administration as a ring 
block around the base of each antler, mean maximum concentrations in plasma (Cmax) of articaine 
were 1,013.9 (SD 510.1) ng/mL, detected at 0.17 (SD 0.00) hours, and the Cmax for articainic acid 
was 762.6 (SD 95.4) ng/mL at 0.50 (SD 0.00) hours. The elimination half-lives of articaine 
hydrochloride and articainic acid were 1.12 (SD 0.17) and 0.90 (SD 0.07) hours, respectively.  
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CONCLUSIONS AND CLINICAL RELEVANCE: The LC-MS method used for the quantification 
of articaine and its metabolite articainic acid in the plasma of red deer was simple, accurate and 
sensitive. Articaine hydrochloride was rapidly absorbed, hydrolysed to its inactive metabolite 
articainic acid, and eliminated following S/C administration as a ring block in red deer. These 
favourable pharmacokinetic properties suggest that articaine hydrochloride should be tested for 
efficacy as a local anaesthetic in red deer for removal of velvet antlers. Further studies to evaluate 
the safety and residues of articaine hydrochloride and articainic acid are required before articaine 
can be recommended for use as a local anaesthetic for this purpose. 
KEY WORDS: Articaine hydrochloride, local anaesthetic, liquid chromatography-mass 
spectrometry, pharmacokinetics, red deer 
Cmax  Maximum concentration in plasma 
DMA  2,6-dimethylaniline 
LC-MS Liquid chromatography-mass spectrometry  
Tmax  Time to reach maximum concentration in plasma  
 
Introduction 
Antlers are unique structures found in cervids which may be cast and regrown annually (Price and 
Allen 2004). Velvet antlers are highly innervated and vascularised cartilaginous structures that are 
harvested for commercial purpose in New Zealand, China, Canada and North America. In New 
Zealand the removal of velvet antlers (velvetting) can only be carried out after desensitisation of the 
antlers (Anonymous 1992). A complete ring block around the antler pedicle, using the local 
anaesthetic lidocaine hydrochloride, is the most widely used and reliable technique to desensitise 
antlers before velvetting (Johnson et al. 2005; Woodbury et al. 2002). However there are concerns 
regarding residues of lidocaine in the harvested velvet antlers (Woodbury et al. 2002; Bagonluri et 
al. 2005). In a limited survey of harvested velvet antlers, lidocaine was detected in 50% of samples 
at concentrations greater than the maximum permitted residue level of 0.1 mg/kg set by the New 
Zealand Food Safety Authority (Clear and Morris 2005). Lidocaine is metabolised by N-
dealkylation in the liver to active metabolites, which are further metabolised to an aromatic amine, 
2,6-dimethylaniline (DMA) (Duan et al. 2008). DMA is classified as potential carcinogen in 
humans (Anonymous 1993) and is hepatotoxic in rats (Duan et al. 20086). It has been reported to 
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increase the incidence of various types of tumours in rats and humans (Anonymous 1990; Beland et 
al. 1997; Duan et al. 2008).  
Articaine hydrochloride (4-methyl-3-(2-propylaminopropionamido) thiophene-2-carboxylic acid 
methyl ester hydrochloride) is a unique amide-type local anaesthetic. It is widely used in humans 
where it is considered to be safe and effective (Oertel et al. 1997; Vree and Gielen 2005; Su et al. 
2016). It is rapidly metabolised to inactive metabolites (mostly articainic acid) by plasma 
cholinesterases, thus decreasing systemic toxicity to the cardiovascular and central nervous systems 
which is common to all local anaesthetics (Snoeck 2012). Toxicity studies of articaine in rats and 
dogs also showed no pathomorphological systemic changes, even after administration of 
systemically toxic doses, and during in vitro and in vivo studies no mutagenic properties were 
associated with articaine, even at cytotoxic concentrations or the maximum tolerated dose 
(Leuschner and Leblanc 1999). 
Given concerns regarding lidocaine residue in harvested antlers and the reported advantages of 
articaine hydrochloride, we propose that articaine hydrochloride may be preferable to lidocaine as a 
local anaesthetic for velvetting in red deer (Cervus elaphus). However it must be noted that 
articaine hydrochloride is not yet approved for use in veterinary medicine and no studies have been 
conducted in animals to evaluate the carcinogenicity of articaine or its metabolites. 
The objectives of this study were to develop and validate a simple and sensitive method using liquid 
chromatography-mass spectrometry (LC-MS) for the quantification of articaine and its metabolite 
articainic acid in plasma of red deer, and to determine the pharmacokinetic parameters of articaine 
hydrochloride following S/C administration as a complete ring block around the base of the antlers 
in red deer.  
Materials and methods 
Reagents and drugs 
Articaine hydrochloride standard (99.9%) was purchased from SCI Pharmtech (Taoyuan, Taiwan) 
and the purity was confirmed using nuclear magnetic resonance crystallography at Massey 
University (Palmerston North, NZ). Articainic acid standard (97%) was obtained from Toronto 
Research Chemicals (Toronto, Canada). Acetonitrile, methanol, water and formic acid were LC-MS 
grade and were purchased from Fisher Scientific (Auckland, NZ). Reagent grade perchloric acid 
was obtained from BDH (Auckland, NZ). Articaine hydrochloride solution (40 mg/mL) was 
prepared freshly on the day of use by weighing an appropriate amount of standard and dissolving it 
in milliQ water. The solution was then filtered through a syringe filter (0.45 µm, Phenomenex Inc, 
Auckland, NZ) and made up to 40 mg/mL with sterile normal saline. 
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Preparation of standards and quality control samples 
Standard stock solutions (1 mg/mL) of articaine hydrochloride and articainic acid were prepared by 
dissolving in water and methanol, respectively. Equal volumes of both stock solutions were mixed 
and working solutions were then prepared by dilution with water. Standard solutions for the 
construction of calibration curves and quality control samples were prepared freshly by adding 
working solutions of either articaine or articainic acid to ice cold pooled plasma obtained from 
untreated red deer. 
Sample preparation 
A 0.5-mL aliquot of ice cold plasma was added to a 1.5 mL microcentrifuge tube and 25 µL of 
perchloric acid was then added and mixed using a vortex mixer for 10 seconds to precipitate 
proteins. After 10 minutes, the samples were mixed again using the vortex mixer then centrifuged at 
20,800g for 10 minutes and 5 µL of supernatant was injected on to the chromatography column.  
Liquid chromatography-mass spectrometry 
Liquid chromatography was carried out using an ultra high performance liquid chromatography 
system equipped with a quaternary pump, a vacuum degasser, a column compartment and an 
autosampler (Dionex Ultimate 3000 System; Thermo Scientific, Germering, Germany). 
Chromatographic separations were achieved using a 2.6 µm particle size C-18 column (100 mm × 
2.1 mm; Accucore, Auckland, NZ) coupled with a security guard column (Defender Guard Column; 
Accucore Auckland, NZ) maintained at a temperature of 30°C. The mobile phase consisted of 0.1% 
formic acid and acetonitrile (70:30, v/v) and was delivered at a flow rate of 0.3 mL/minute.  
Mass spectrometric detection was performed using a hybrid quadrupole orbitrap mass spectrometer 
(Q Exactive Focus Hybrid Quadrupole-Orbitrap Mass Spectrometer; Thermo Scientific, Bremen, 
Germany) with an electrospray-ionization interface. Positive ion electrospray ionization-mass 
spectrometry was used for analysis of both articaine and articainic acid. Mass spectrometry 
conditions are given in Table 1. Data processing was performed using the Xcalibur data system 
(Thermo Scientific) and quantitation was performed in the full scan MS mode using peak-area 
ratios of the target ion of articaine (mass to charge ratio 285.16) and articainic acid (mass to charge 
ratio 272.11). Samples which exceeded the calibration limit were appropriately diluted with drug-
free plasma and reanalysed. 
Validation 
The linearity of the LC-MS method was determined by linear regression analysis. Calibration 
curves were constructed using three replicates of pooled plasma obtained from untreated deer 
spiked with working solutions of either articaine hydrochloride or articainic acid, at concentration 
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ranging between 5–2,000 ng/mL and 10–1,000 ng/mL, respectively. The lower limit of detection 
and quantification of the compounds were set at signal to noise ratios of 3:1 and 10:1, respectively. 
Recoveries of articaine hydrochloride and articainic acid from red deer plasma after extraction were 
calculated by measuring the peak areas for three replicate samples of plasma from untreated deer 
containing 20, 200 and 1,000 ng/mL of quality control standards, following the same sample 
preparation procedure described above. Specificity of the method was determined by comparing the 
chromatograms of blank plasma samples obtained from six untreated deer and a spiked plasma 
sample containing 20 ng/mL of articaine and articainic acid.  
Intra-day and inter-day precision and accuracy of the method were determined by processing three 
replicates of plasma samples from untreated deer containing three concentrations (20, 200 and 
1,000 ng/mL) of analytes six times on one day, and on six different days, respectively.  
Carry-over from the system was assessed by injecting a drug-free plasma sample after injection of a 
plasma sample containing either articaine or articainic acid at concentrations equivalent to the 
respective upper limit of quantification. 
Animals and experimental procedure 
Six healthy 2-year-old male red deer weighing between 105–116 kg were used for this study. The 
experimental protocol was approved by Massey University Animal Ethics Committee (Palmerston 
North, NZ) and the study was conducted at Massey University Deer Research Unit (Palmerston 
North, NZ).  
Each red deer was physically restrained in a hydraulic crush, the hair around the base of antlers was 
clipped and the pedicle circumference of each antler was measured using a measuring tape. The left 
or right facial vein was surgically prepared and a 20 gauge, 48 mm I/V catheter (BD Insyte, Sandy, 
UT, USA) was placed and secured with cyanoacrylate adhesive (Super Glue; Loctite, Auckland, 
NZ). The patency of the catheter was maintained using heparinised (10 USP/mL) saline.  
Within 5 minutes of catheterisation, articaine hydrochloride (40 mg/mL) at a dose of 1 mL/cm of 
pedicle circumference was administered S/C as a complete ring block (4–5 injections) around the 
base of both the antlers using a 20 gauge needle attached to a 20 mL syringe. The syringe plunger 
was pulled back prior to infiltration to ensure the needle was not in a blood vessel. The time taken 
for drug administration did not exceed 2 minutes in any of the animals. Blood samples were 
collected, via the catheter in the facial vein, into heparinised vacutainers (BD Vacutainer, Plymouth, 
UK) prior to drug administration (0 minutes), and 10, 20, 30, 40 minutes and 1, 2, 4, 6, 8, and 12 
hours following drug administration. Immediately after collection, blood samples were cooled on 
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ice and plasma was separated and stored at −20°C. LC-MS analysis was carried out within 1 month 
of sample collection.  
For 2 hours after drug administration animals were visually observed for adverse signs such as 
muscle tremor, sedation or convulsion while unrestrained in a pen. 
Pharmacokinetic analysis  
Pharmacokinetic parameters were determined using non-compartmental analysis. The PKSolver 
add-on (Zhang et al. 2010) for Excel 2010 (Microsoft, Redmond, CA, USA) was used to calculate 
pharmacokinetic parameters using individual concentrations of articaine and articainic acid in 
plasma. The maximum concentration in plasma (Cmax) and time to achieve Cmax (Tmax) were 
determined directly from the curves of plasma concentrations over time. The rate constant of the 
terminal phase (λz) was calculated by linear regression of the logarithmic plasma concentration and 
the terminal half life was calculated as: 
t½λz = ln2/λz 
The area under the curve (AUC) and the area under the first moment curve (AUMC) were 
determined using the linear trapezoidal method. Mean residence time was calculated as:  
MRT = AUMC/AUC 
Results 
LC-MS validation 
Calibration curves (Supplementary Figure 11) were linear with correlation coefficients of 0.997 for 
articaine and 0.998 for articainic acid. The lower limits of quantification were 5 ng/mL and 10 
ng/mL, and the lower limits of detection were 1 ng/mL and 5 ng/mL, for articaine and articainic 
acid, respectively. The assay intra-day CV for articaine and articainic acid were <5.7 and 5.3%, 
respectively, and the inter-day CV for articaine and articainic acid were <12.8 and 10.7%, 
respectively. The extraction recoveries for articaine ranged from 72–79% and for articainic acid 
from 68–75% (Table 2). No carry-over effect was found when a drug-free plasma sample was 
injected after a sample containing concentrations of the analytes equivalent to the upper limit of 
quantification. Analysis of six blank plasma samples from untreated deer showed no interfering 
peak on the chromatograms at the retention times of articaine or articainic acid. 
Representative chromatograms and electrospray ionization full scan MS mode are shown in 
Supplementary Figure 21 for plasma samples that were drug-free, or spiked with 20 ng/mL of 
                                                 
1 https://doi.org/10.1080/00480169.2017.1391141 
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articaine and articainic acid, or from a red deer following S/C administration of 40 mg/mL articaine 
hydrochloride as a complete ring block around the antlers. 
Pharmacokinetics 
No signs of adverse effects were observed in any animal following administration of articaine 
hydrochloride. Mean concentrations in plasma of articaine and its metabolite articainic acid 
following S/C administration of articaine as a ring block are shown in Figure 1. Peak concentrations 
of articaine in plasma were detected in the sample collected 10 minutes after drug administration, 
which was the first sample collected. Concentrations in plasma of articaine hydrochloride and 
articainic acid were above the limit of quantification for 6 and 4 hours after administration, 
respectively. The pharmacokinetic parameters both compounds following S/C administration of 
articaine hydrochloride as a ring block are shown in Table 3.  
Discussion 
The LC-MS method described here for measurement of articaine and its metabolite articainic acid 
in the plasma of red deer is simple and sensitive with acceptable precision and accuracy. The 
sensitivity of the LC-MS method was greater than previously reported methods with a lower limit 
of quantifications of 5 ng/mL and 10 ng/mL for articaine and articainic acid, respectively. Richter 
and Oertel (1999) reported a lower limit of quantification of 10 ng/mL for articaine using an HPLC-
based method and Hoizey et al. (2009) reported a lower limit of quantification of 78.1 ng/mL for 
articaine using a different LC-MS method. The sample preparation method used here involved a 
simple protein precipitation step which yielded good recoveries of the analytes. Previously reported 
extraction methods used liquid-liquid extraction or a solid phase extraction step followed by drying 
(Richter and Oertel 1999; Hoizey et al. 2009), which are more time consuming than the simple 
protein precipitation step used in our method.  
This is the first study to investigate the pharmacokinetics of articaine hydrochloride and its 
metabolite articainic acid in red deer. Following S/C injection, articaine hydrochloride was rapidly 
absorbed with a mean Cmax of 1013.9 ng/mL and Tmax of 0.17 hours. The time when maximum 
concentrations were detected was when the first sample was collected after administration of 
articaine, therefore in future studies blood samples should be collected earlier than 10 minutes after 
administration to more accurately determine the Cmax and Tmax. Rapid absorption of the articaine 
hydrochloride can be attributed to its vasodilatory effect, similar to most other local anaesthetics 
(Snoeck 2012). The rapid absorption of articaine hydrochloride has also been reported in humans 
following oral nerve blocks and epidural administration (Muller et al. 1991; Vree et al. 1997).  
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The mean terminal half-life of 1.12 hours indicates that articaine is rapidly eliminated following 
S/C administration in red deer. Articaine was rapidly hydrolysed to its metabolite articainic acid, 
with maximum concentrations of articainic acid being detected 30 minutes after administration. 
Rapid hydrolysis has been reported to be due to the presence on the articaine molecule of an ester 
group, which makes it a suitable substrate for plasma esterases (Oertel et al. 1997). Articainic acid 
was also eliminated rapidly with a mean terminal half-life of 0.90 hours. Pharmacokinetic studies in 
humans found that articaine was excreted primarily as articainic acid (64%), and the glucuronide 
conjugate of articainic acid (13%). Only 1.5% was excreted as the parent drug, articaine 
hydrochloride (Vree et al. 1997).  
No signs of toxicity associated with over-dose of local anaesthetic, such as muscle tremor, sedation 
or convulsion, were observed following administration of articaine hydrochloride in the current 
study. Rapid hydrolysis of articaine hydrochloride by plasma esterases to an inactive metabolite 
results in short half-life of the drug thereby reducing the risk of systemic toxicity (Oertel et al. 
1997). In contrast, lidocaine hydrochloride is metabolized to active metabolites which require 
hepatic clearance. In addition, in vitro and in vivo preclinical toxicity studies in rats, rabbits and 
dogs indicated that articaine hydrochloride did not demonstrate any pathomorphological or 
mutagenic effects at doses up to 70 mg/kg (Leuschner and Leblanc 1999).  
In conclusion, a method for the detection and quantification of articaine and articainic acid using 
LC-MS was developed and validated, and found to be simple, accurate and sensitive. Articaine 
hydrochloride was shown to have favourable pharmacokinetic properties in red deer including rapid 
absorption, hydrolysis and elimination. Moreover, we observed no adverse effects following S/C 
administration of articaine hydrochloride as a complete ring block around the antler pedicle in red 
deer. Articaine hydrochloride may therefore be a good alternative to the commonly used local 
anaesthetic lidocaine for velvetting in red deer. Use of articaine hydrochloride in animals has not 
been authorised in any animal species and further studies are required to evaluate the safety and 
efficacy of the drug at different concentrations, and to establish maximum residue limits, before it 
can be recommended for use as a local anaesthetic in red deer.  
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Table 1. Mass spectrometry conditions for the quantification of articaine and articainic acid 
in the plasma of red deer (Cervus elaphus). 
Parameter Value 
Resolution setting 70,000 
Mass range 100.0–500.0 m/z 
Spray voltage 3.3 kV 
Sheath gas flow rate 30.0 arbitrary units 
Auxiliary gas flow rate 5.0 arbitrary units 
Capillary temperature 320°C 
Heater temperature 350°C 
Radio frequency lens level 50.0 
HCD collision energy 35 eV 
HCD=higher energy collisional dissociation; m/z=mass-to-charge ratio 
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Table 2. Mean (±SD) recovery (%) of articaine and articainic acid spiked into drug-free 
plasma from red deer (Cervus elaphus) at three different concentrations, after extraction 
and detection using liquid chromatography-mass spectrometry. 
Concentration 
(ng/mL) 
Articaine Articainic acid 
20 75.7±1.3 75.6±3.1 
200 79.0±4.9 68.9±1.4 
1,000 72.4±3.9 72.2±4.0 
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Table 3. Mean (±SD) pharmacokinetic parameters of articaine and articainic acid following 
S/C administration of 40 mg/ml articaine hydrochloride (1 mL/cm pedicle circumference) as 
a complete ring block around the antler pedicle of red deer (Cervus elaphus; n=6).  
Parameter Articaine Articainic acid 
Maximum plasma concentration (ng/mL) 1013.9±510.1 762.6±95.4 
Tmax (hours) 0.17±0.00 0.50±0.00 
AUC (ng/mL.hour) 936.9±157.1 1196.0±80.7 
AUMC (ng/mL.hour) 1326.5±151.0 1701.7±93.1 
Terminal half life (hours) 1.12±0.17 0.90±0.07 
Mean residence time (hours) 1.45±0.29 1.43±0.08 
AUC=Area under the curve; AUMC= Area under the first moment curve; Tmax=Time to reach maximum 
plasma concentration 
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Figure 1. Mean (±SD) concentrations of articaine (solid line) and articainic acid (dotted line) 
in plasma of red deer (Cervus elaphus; n=6) following S/C administration of 40 mg/mL 
articaine hydrochloride (1 mL/cm pedicle circumference) as a complete ring block around 
the antler pedicle. Note the log scale of the y-axis.  
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